Keith Speights

Keith Speights

TMFFishBiz

Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.

Recent articles












Why ImmunoGen Shares Are Crashing Today

Disappointing news from the FDA means that the biotech company is further from potentially winning approval for its lead drug candidate.